These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28181840)

  • 1. Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis.
    Chen S; Han Y; Yu D; Huo F; Wang F; Li Y; Dong L; Liu Z; Huang H
    Drug Deliv; 2017 Nov; 24(1):467-470. PubMed ID: 28181840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the efficacy of drug transdermal delivery by electro-phonophoresis in treating tuberculous lymphadenitis.
    Chen S; Qin M; Han Y; Zhao L; Fu Y; Shang Y; Liu Z; Huang H
    Drug Deliv; 2016 Jun; 23(5):1588-93. PubMed ID: 26669820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug transdermal delivery by electrophonophoresis can increase the concentration of rifampicin in the pleural effusion of patients with tuberculous pleurisy but has no effect on the concentration of rifampicin in plasma.
    Liu Q; Chen L; He JQ
    Int Immunopharmacol; 2023 Apr; 117():109892. PubMed ID: 37012884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 5. The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus).
    P Brock A; Isaza R; Egelund EF; Hunter RP; Peloquin CA
    J Vet Pharmacol Ther; 2014 Oct; 37(5):472-9. PubMed ID: 24684601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs.
    Anjani QK; Permana AD; Cárcamo-Martínez Á; Domínguez-Robles J; Tekko IA; Larrañeta E; Vora LK; Ramadon D; Donnelly RF
    Eur J Pharm Biopharm; 2021 Jan; 158():294-312. PubMed ID: 33309844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurement of rifampicin concentrations in tuberculous pleural effusion before and after combination treatment with oral and local rifampicin].
    Liu QX; Guo DT; Chen L; Ou SP; Huang L; Yan H; Zheng XC; Weng CX; Zhang JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Nov; 41(11):853-856. PubMed ID: 30423627
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.
    Rajaram S; Vemuri VD; Natham R
    J Pharm Biomed Anal; 2014 Nov; 100():103-108. PubMed ID: 25151231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
    Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC
    Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
    Deol P; Khuller GK; Joshi K
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1211-4. PubMed ID: 9174172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.
    Mariappan TT; Singh S
    Int J Tuberc Lung Dis; 2003 Aug; 7(8):797-803. PubMed ID: 12921157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
    Xu W; Wei X; Wei K; Cao X; Zhong S
    Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to in vivo testing.
    Genina N; Boetker JP; Colombo S; Harmankaya N; Rantanen J; Bohr A
    J Control Release; 2017 Dec; 268():40-48. PubMed ID: 28993169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.